The FDA decision on Roche Holding AG’s (RHHBY.OB) Mosunetuzumab, a T-cell-engaging novel cancer immunotherapy, is expected on December 29, 2022.Mosunetuzumab is proposed for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior systemic therapies and is under priority review. Follicular lymphoma is the most common indolent (slow growing) form of non-Hodgkin’s lymphoma (NHL), a type of blood cancer, which often returns after initial therapy. The European Commission approved Mosunetuzumab, under brand name Lunsumio, for relapsed or refractory follicular lymphoma, in June of this year.Analysts expect the drug to achieve peak sales anywhere between $500 million and $1 billion.RHHBY.OB closed Friday’s trading at $41.06, up 1.08%.